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Scope and Method of Study: The sudden onset of the acquired 
immunodeficiency syndrome (AIDS) in Oklahoma in January of 1983 has 
created some very serious problems for health care providers. The 
high costs related to the medical management of AIDS patients have 
resulted in significant financial burdens for a number of Oklahoma 
hospitals. In order to formulate a strategic plan for coping with 
future hospital admission costs associated with the increasing 
number of AIDS victims, a forecast relating the extent of the 
potential problem is necessary. The objective of this study is to 
provide that forecast by combining historical hospital admission 
costs for AIDS patients in Oklahoma with a computer forecas t of 
expe cted new cases over the next three years. Eight hospitals, 
which managed 87 percent of the reported AIDS cases, provided 
admission-cost figures for 71 percent of the cumulative Oklahoma 
morbidity. The Interactive Financial Planning System (IFPS) was 
employed to derive anticipated case totals for each of the three 
calendar years. 
Findings and Conclusions: Although the average Oklahoma AIDS patient 
survives only four months afte r diagnosis, the hospital admission 
charges total approximately $25,000 per patient. This is based on 
observed figures, which indicate an average of 35 hospital days at 
$708 per patient per day. The predictions for new AIDS diagnoses 
for 1986, 1987, and 1988 reached 44, 69, a nd 100 respectively. In 
combining these numbers with average cos t figures, charges f o r 
hospital a dmissi ons are expected to reach $1.1 million in 1986, $1.7 
mi ll i on in 1987, and $2.5 million in 1988. Thi s reflec ts a $5 .3 
million total for the next three years, in terms of hospital 
admis s i ons only, for medically managing AIDS patients. 
A THREE-YEAR FORECAST OF HOSPITAL ADMISSION 




I wish to express my sincere appreciation to Dr. James w. Gent r y f or 
his patience and expert direction in advising me in this undertaking. I 
also wish to thank Dr. Ronal d K. Miller for his meaningful guidance in my 
course of studies at Oklahoma State University . 
Special thanks a r e due to Dan Cameron and the Sexually Transmitted 
Disease Division of the Oklahoma State Department of Health for 
invaluable help and relevant comments. I am especially grateful to a l l 
the ho s pitals which supplied me with pertinent data . I am una ble t o l ist 
them in order to insure their confidentiality, but they know who they 
are. 
i ii 
TABLE OF CONTENTS 
Chapter Page 
r. INTRODUCTION. 
General Statement •• 
Consequences • . • • 
Type of Virus •••• 










II. REVIE'ol OF AIDS. 8 
Realization of Problem • 
Evidence for an Infective Agent. 
I dentification of the Virus •• 
Viral Origin . 






III. METHODOLOGY .... 20 
IV. 
Information Gathering. 
Forecasting Technique .• 
Results and Forecasts. 





Difficulty of · the Situation. 28 
Positive Approaches. 32 
REFERENCES . 36 
APPENDICES . 40 
APPENDIX A - DEMOGRAPHIC BREAKDOHN OF REPORTED AIDS CASES 
IN U.S. . . . . . . . . . . . • 4 1 
APPENDIX B - SAMPLE OF AIDS CASE REPORT FORM LISTING 
DIAGNOSTIC OPPORTUNISTIC INFECTIONS. . 43 
APPENDIX C - AIDS CASES IN U.S. BY SELECTED SMSA'S. 45 
APPENDIX D - REPORTED AIDS CASES AND FATALITY RATES BY 
HALF-YEAR OF DIAGNOSIS IN THE U.S. . . 47 
iv 
Chapter Pag e 
APPENDIX E - DIAGRAM OF RETROVIRUS ...... . 49 
APPENDIX F - CUMULATIVE TOTALS OF AIDS CASES IN OKLAHOMA 
THROUGH 1985 . . . . . . . . • . . . . . . 51 
APPENDIX G - GRAPHIC REPRESENTATION OF KNOWN AND PRED ICTED 





The acquired immunodeficiency syndrome (AIDS), in a very short 
period of time, ha s attained a position of national notoriety. The 
sudden appearance of this new debilitating disease with ultimately fatal 
consequences has created cons t ernation among medical scientists and panic 
withi n the general population. Although a vast amount of knowledge has 
been gathered concerning AIDS since the identification of this condition, 
much is still unknown and only time will permit a full understanding. 
And, as i s true in most areas of medicine and disease control, clear-cut 
definitive answers do not exist for every individual situation or 
contingency. Unfortunately, much media attention has focused on various 
inflammatory, yet extremely unlikely, modes of transmiss ion and thus 
contributed to mass confusion. 
Consequences 
First recognized in the United States in 1981, AIDS had been 
diagnosed in approximately 16,000 individuals by the end of calendar year 
1985. The s eriousness of this syndrome is obvious in the overall 
mortality rate of 51 percent. Appendix A illustrates this mortality and 
the demographic breakdo~vn of reported AIDS cases in the United States . 
This is compounded in significance by the fact tha t nationally the 
1 
2 
survival period from time of diagnosis has a mean of 18 months. In 
reviewing cases diagnosed prior to 1983, the mortality reaches 77 percent 
in those patients whose final disposition was reported to the Center for 
Disease Control (CDC, 198Sb). Many of those reported cases eluded 
epidemiological evaluation after the definitive diagnosis, and 
consequently the actual death rate is believed to be even higher. 
AIDS represents only the final stages of infection by the human T-
cell lymphotropic virus type III (HTLV-III) or the lymphadenopathy-
associated virus (LAV) (Curran, 1985). Both names refer to the same 
entity. This virus actually invades and substantially weakens or even 
destroys the cells which form an integral segment of the body's immune 
system, thus inhibiting or eliminating the normal defenses. As a result, 
commonly occurring, and usually insignificant, infective agents become 
invasive to the compromised host and subsequently create life-threatening 
situations. These disease-producing organisms are referred to as 
opportunistic infections, owing to the fact that they are able to exploit 
the host organism only after the natural immune system is depressed. 
Type of Virus 
The HTLV-III/LAV organism is actually a retrovirus, a classification 
of virus that was unknown as few as 10 years ago (Gross, 1983). 
Scientists have only recently developed the technology necessary to 
identify the type of viral replication which determines the specific 
classification. Until the evolution of AIDS, retroviruses were believed 
to have only minor roles in the area of human disease and therefore had 
not attracted much attention in terms of medical management or disease 
control r esearch. For retroviruses , as with most other t ypes of viral 
agents, no cure exists once they have invaded the body. Vaccines are 
possible but difficult due to viral mutagenicity. 
Medical Management 
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The symptomatic conditions, serving as indicators for the 
HTLV-III/LAV infection, have dictated the course of medical management 
(Merigan, 1984; Armstrong, Gold, Dryjanski, Whimbey, Polsky, Hawkins, 
Brown, Bernard and Kiehn, 1985). While research is directed toward a 
cure for the infected and immunization for those at risk of acquiring the 
disease, applicable developments are still many years away. Broad 
spectrum treatments for AIDS victims are currently limited to 
experimental drugs, which range in function from T-helper cell 
enhancement to viral replication suppression (Hirsch and Kaplan, 1985). 
These drugs, approved through the Federal Drug Administration on a case-
by-case basis, are very expensive and often have dangerous or unknown 
side effects. Considering the prognosis for the AIDS sufferer, FDA 
releases have not been especially difficult to obtain. However, the 
debilitating nature of the syndrome still presents a general barrier to 
productive employment for the AIDS victim, and often the expense of these 
particular medications and the requirement for administration in a 
hospital setting make their obtainment prohibitive. 
The medical services most often required by AIDS victims are in 
response to the diagnosing and managing the episodes of opportunistic 
infections. These ''products" of the syndrome generally occur singly or 
in combinations and are often severe enough to require hospitalization. 
Additionally, because these maladies a re, or have the potential of 
rapidly becoming life-threatening, hospital needs include more 
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specialized services such as the employment of sophisticated life support 
equipment, constant monitoring, and even the regular use of intensive 
care facilities (Landesman, Ginzburg, and Weiss, 1985; Volberding, 1985). 
Since the opportunistic agents are so common in the environment, the AIDS 
patient can be subject to frequent and prolonged hospitalizations, and 
the resulting hospital bills can be staggering, yet largely unavoidable 
in the current procedural guidelines. 
Historical Expens es 
Due to the sudden onset of this entirely new syndrome, most private 
physicians were unequipped to recognize the relationship of the 
opportunistic infections and how to make the diagnosis of AIDS. As a 
result, a great majority of the diagnoses came to realization through 
hospital admission and an accompanying battery of extensive tests. Many 
times the pat i ent, too, was unaware until a life-threatening circumstance 
developed and required i mmediate hospita lization. Those attending 
hospitals soon found themselves with large investments and little hope of 
recouping their losses. 
Those expens es associated with the medical management of AIDS 
patients have been astronomical. Estimates of expenditures for the first 
10,000 patients with AIDS reported in the United States amounted to $1.4 
billion for hospital utilization (Hardy, Rauch, Echenberg, Morgan, and 
Curran, 1986). As the number of infected individuals continues to 
increase, these related cos ts will a lso rise, creating an even greater 
economi c burden. Major controversies already flourish regarding how 
these expenses will be absorbed and by whom . Suggestions have included a 
direct national ef fo rt of major proportions to coordinate and financ ially 
support activities in the health care system aimed at managing the AIDS 




The State of Oklahoma will not be free of these specific issues 
either. While the volume of AIDS cases may not be as severe as in other 
areas of the country, the situation does require attention as the ~umber 
of patients diagnosed with AIDS is significant and expected to increase. 
The first reported case of AIDS occurred in Oklahoma in 1983, and 
subsequently, four additional cases were diagnosed in that calendar year. 
For 1984, the new reports equalled 12 , and in 1985, diagnosed infections 
reached 25. Although this reflects only 42 total cases in the three-year 
period, the rate of increase is substantial and any available control 
measures have yet to prove their real value. 
In order to formulate a strategic plan for coping with the potential 
economic impact, the forecasting of AIDS morbidity is necessary to define 
t he magnitude of the problem. Hospitals have rapidly become cognizant of 
the difficulties in recove ring their costs , and insurance companies are 
currently s eeking methods of avoiding or limiting their outlays in the 
AIDS epidemic. Federal, state, and local governments cannot ignore this 
situation since health issues of this proportion will affect everyone. 
The greater the severity of the AIDS epidemic in Oklahoma, the greater 
the pressures on community organizations and state agencies to provide 
financial support to health ca re facilities and gene r a l assistance to the 
victims . This is more essential and ye t even more problematic in light 
of the current generally depressed economic conditions plaguing Oklahoma. 
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This paper is an effort to establish, for each of the next three 
years, an estimate of total hospital costs associated with managing AIDS 
patients in Oklahoma. This estimate will be vital for hospitals facing 
the greater demand on their services in this epidemic. This is also an 
essential step for the recently formed AIDS Program within the Sexuall y 
Transmitted Disease Division of the Oklahoma State Department of Health, 
in order to formulate program goals and objectives, and to provide 
recommendations to the State Legislature in terms of legislative and 
supportive actions. However, in view of intensive worldwide research and 
the rapid accumulation of new knowledge regarding HTLV-III/LAV 
infections, any projection over three years would be beyond the scope of 
current developments. 
Several factors need to be evaluated in order to arrive at a 
realistic forecast in this set of particular circumstances. First, a 
projection of the expected number of newly diagnosed cases of AIDS 
establishes a volume figure. Second, historical costs inc urred by 
Oklahoma hospitals in managing past AIDS victims provide financial gui des 
for future expectations. However, at the present time, no common 
denomina tor has been identified among infe cted individ uals or within t he 
opportunistic infections which would account for the inconsistencies in 
survival time or variation in the number and duration of required 
hospitaliza t i ons. And thir d, an inflation index for hospi tal costs in 
Oklahoma f acili t ies i s usefu l i n adjus ting cos t s to current do l lars over 
the observed period of time. This should provide a clearer picture of 
the fiscal needs for at least short-run planning. 
Al though AIDS itsel f represents the " tip of the iceberg" in t he 
HTLV-III/LAV infection, the hospital costs fo r medical management have 
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been paramount. Those infected with the virus, but who do not 
technically meet the strict epidemiological definitions of AIDS, often 
require medical treatment for a series of minor infections and 
symptomatic responses (Virginia Health Department, 1985). However, the 
expenses incurred in their management are significantly less than the 
costs associated with the specialized hospital care and sophisticated 
equipment required in treating the AIDS victim. Without a specific 
definition for other conditions related to the viral infection, reporting 
is ineffective and irregular. This makes an accurate accounting 
impossible. 
The debilitation associated with AIDS forces most victims to a 
dependency on governmental or community support for survival, even though 
these resources are insufficient in their current level of operation. 
The state agencies will bear the brunt of administering thes e programs, 
supplemented with the financial aid of all government levels. The health 
care providers will also feel the severe financial crunch and mu$t be 
prepared to deal with the epidemic, since the amount of any government 
aid will most likely be restricted. With the potentia l for such a large 
economic threat, the time for planning is now, and the first basic step 
is to try to gain a feel for just how great the potential problem is. 
CHAPTER II 
REVIEW OF AIDS 
Realization of Problem 
The first public indications that a significant medical emergency 
had arisen were reports appearing in the spring of 1981 (CDC, 1981a; 
Gottlieb, Schroff and Schanker, 1981). The initial writings centered 
around the diagnosis of pneumocystis carinii pneumonia (PCP) and candidal 
mucosal infections in several previously healthy homosexual males. These 
patients had been diagnosed in various hospitals in Los Angeles between 
October 1980 and May 1981, and many had already died. These reports were 
of particular concern since, in the United States, pneumocystic pneumonia 
is extremely r a r e exc ept i n patients with severely compromised immune 
systems. Of those patients tested, all showed evidence of abnormal 
cellular-immune function brought on by unknown causes. 
In July of 1981, the Morbidity and Mortal ity Weekly Report (CDC, 
198lb) described 26 young homosexual males who were diagnosed in 
California and New York City as having Kaposi's sarcoma (KS). The 
article a lso points out that this malignancy is r a re in the United States 
with an annual estimated incidence of 0.02-0.06 cases per 100,000 persons 
and generally affects only elderly males of Mediterranean descent. The 
disease manifestations range from s l owly advancing vascula r nodules on 
t he skin t o extensive involvement of other organs. Of the young men 
referred to in this article, eight had passed away within 24 months of 
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diagnosis. As both PCP and KS are typically manifest in immunosuppressed 
individuals, scientists began searching for a link in the homosexual 
lifestyle that might shed light on a causative agent of this i mmune 
deficiency. 
Evidence for an Infective Agent 
Because of similarities in transmission patterns to that of 
hepatitis B, a viral entity was suspected to be the causative agent. The 
types of sexual activities inherent in the gay lifestyle, large numbers 
of sexual partners, and use of inhalant drugs such as amyl or butyl 
nitrates were all believed to be potential factors in disease 
transmission and/or progression (Marmour, Friedman-Kien, and Laubens tein, 
1983; Jaffe, Hardy, Morgan and Darrow, 1985). Additional research has 
indicated receptive rectal intercourse as a primary mode of transmis sion, 
and risk of infection does parallel increased numbers of casual sex 
partners (Da rrow, Jaffe, and Curran, 1983). The inhaled drugs, "popper, 
have been indicated as a coincidental occurrence or possibly a 
procarcinogen to KS (CDC, 1983). 
During t he last half of 1981 and early 1982, a greater number of 
opportunistic infections were indicated as having a specific rela tionship 
t o the increasing number of diagnosed immunosuppressed patients (CDC, 
1982a). By definition, these diseases t ake advantage of the depleted 
body defenses i n invading the host organism and can become debilitating 
to the point of causing death in the host. For epidemiological purposes, 
the more significant of these infections have been targeted for reporting 
(Appendix B). 
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While the first incidences of this unusual condition \vere reported 
in young male homosexuals, the same apparent malady was discovered in 
intravenous drug abusers who shared needles with other users, in 
hemophiliacs, and in recipients of other blood products (Cohen, Marmour, 
DesJarlais, Spiral, Friedman, and Yancovitz, 1985; Eyster, Goedert, and 
Sarngadharen, 1985). This l ent support to the theory that the infective 
organism was present in and capable of transmi ss i on through blood and 
blood products. Another group demonstrating a high incidence of the 
syndrome were immigrants from Haiti. This last segment was questionabl e 
since they did not offer any of the potential risk factors which were 
more obvious in the other named groups. 
In 1982, the Center f or Disease Control published a name for this 
r e cognized medical condi t i on (CDC, 1982b). Acquired immunodeficiency 
syndrome (AIDS) became the widely accepted nomenclature for referring to 
the consequent i al condition of the i mmune suppression. I n order to 
outline case r eporting for d i sease surveillance, CDC defined AI DS on two 
basic criteria. One was the pres ence of a reliably diagnosed disease at 
least moderately indicative of cellular immune deficiency, and second, 
t he absence of an underlying cause for t he i mmune deficiency or reduced 
res istance . 
The earliest reported cases of AIDS revealed significant 
concentra t ions of i nfection by standa rd metropolita n statis tical a reas of 
r es ide nce in a f ew coas tal states of the continental u.s. (Appendix C). 
The SMSA's wi th the highest i ncidence of AI DS a re also areas of 
compar a tively high concentrations of homosexual males and IV drug users . 
In New York City and Newark, New J ersey , " shoot i ng gall er ies" a r e popular 
a mong drug addict s . In thes e galleries , drug user s s hare needles by 
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passing a syringe from one person to another. This practice provides a 
distinct opportunity for exposure to the blood of others through multiple 
use of potentially contaminated needles. Another breakdown in six-month 
periods (Appendix D) reflects the known morbidity of cases diagnosed and 
reported, and the corresponding de~th rate over time. The a rea morbidity 
and high death rates are consistent. 
Another at-risk segment of the U.S. was officially recognized toward 
the end of 1982. This included hemophiliacs and recipients of blood 
transfusions. The risk to hemophiliacs for exposure to AIDS came through 
the treatment of their disease with concentrated clotting factors. These 
concentrates, particularly Factor VIII, were derived from the pooled 
plasma of 2,500 to 25,000 donations (Levine, 1985). Thus, an individual 
with hemophilia could be exposed to the plasma of a great number of often 
commercial donors with each treatment with Factor VIII. The fact that 
some AIDS patients had no identifiable risk factor other than receiving 
blood transf usions led the Public Health Service to recommend that 
persons belonging to any of the named risk categories refrain from 
donating blood, blood products, or other body fluids and organs (CDC, 
1983a). 
Another means of transmission was observed in infants born to 
infected parents. Those newborns were diagnosed as having AIDS by ruling 
out other immune dysfunctional diseases and by confirming the presence of 
the familiar oppor tunist ic infections (CDC, 1982c ). Few of these 
infected newborn survived for a period of more tha n a few months. The 
sequence of occurrences added more support to the search for an infective 
agent in body fluids and particularly in blood. 
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Identification of the Virus 
In 1983, a new virus was isolated at the Pasteur Institute in Paris, 
France, from a patient with persistent generalized lymphadenopathy 
(Barre-Sinoussi, 1983). This was actually a retrovirus and was labeled 
the lymphadenopathy associated virus (LAV). The isolation of a similar 
retrovirus was reported in the United States in 1984 and was named the 
human T-cell lymphotropic virus (HTLV-III) (Gallo, Saladhuddin, and 
Popovic, 1984; Popovic, Sarngadharan, Read, and Gallo, 1984; 
Sarngadharan, Popovic, and Bruch, 1984), or AIDS-associated retrovirus 
(ARV) (Levy, Hoffman, and Kramer, 1984). These independent isolations 
have proven to be a single strain of retrovirus, generally referred to in 
the u.s. as HTLV-III/LAV or just HTLV-III. All human retroviruses have 
the characteristic affinity for !-lymphocytes, or T-helper cells, which 
are a major component of the body's immune system. The T-cells control 
host antibody production. 
Retroviruses were first isolated and classified as a separate gro up 
in 1979 (Poiesz, Ruscetti, and Gazdar, 1980). The initial retrovirus, 
associated with adult T-cell leukemia, was the human T-cell lymphotropic 
virus (HTLV-I). Another member · of this family was discovered shortly 
afterwards in a patient with a T-cell variation of hairy cell leukemia, 
and was named HTLV-II. Both of these retroviruses have been isolated 
from AIDS patients, although the HTLV-III is viewed as the specific 
causative agent . 
Re troviruses are significantly different f r om other viruses in tha t 
they carry their genetic codes in ribonucleic acid ( RNA) , while the bulk 
of living organisms carry t heir genetic information in deoxyribonucleic 
acid (DNA). Therefore, the r e trovirus groups present some very difficult 
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situations. The retrovirus, upon entering a cell, employs a self-
contained enzyme called reverse transcriptase to translate specific RNA 
codes into the DNA of the host cell. Having then become part of the host 
cell, the viral code may lie dormant for periods up to a great number of 
years, and in fact, the latency period of viral infection to development 
of AIDS can be 1 to 7 years and possibly longer. Yet every time an 
infected cell replicates, the viral code is reproduced in the new cell. 
To infect other normal cells, the retrovirus information must be 
translated back into the RNA strands which are released to repeat the 
process of infecting healthy cells. The replicative actions involving 
reverse transcriptase have proven to be ve ry error-prone processes. This 
has created a situation of numerous mutations of the virus, even within a 
single host organism. Over 100 isolates have been identified to date 
(Gallo and Wong-Staal, 1985), and as a consequence, development of a cure 
or even a vaccine will be extremely difficult. 
When the dormant HTLV-III/LAV activates, the host cell functions as 
the viral code dictates. This leads to a serious inhibition of the 
normal operation to the extent that host cell is severely weakened or 
even killed. The T-helper 'cells become fewer in number, significantly 
attenuated, and die more quickly, and as a result the body's immune 
system is much les s effective in resisting infection. Current resea rch 
suggests that the invasive HTLV-III/LAV is activated when the host immune 
system in general has been activated (Blattner, Biggar, Weiss, Melbye, 
and Goedert, 1985). This would sugges t that any type of disease-causing 
agent or other infection, by stimulating an immune r es ponse in a 
contaminated individual, could activate the already present virus and in 
effect cause the T-lymphocytes to self ~estruct. Therefore, repeated 
infections or even additional exposures to the body fluid s on one 
carrying the virus could stepwise depress the host immune system to the 
point that AIDS would have a greater likelihood of occurring. 
The HTLV-III/LAV has been isolated from a number of body fluids, 
including blood , semen, saliva, and tears. The greatest concentrations 
of the virus, and consequently the greatest potential for transmission, 
have been found in blood and semen. The concentrations in saliva and 
tears make transmission from those fluids ex tremely unlikely, yet not 
impossible. This is supported by the findings tha t the greatest number 
of AIDS cases by far give histories of exposure to the blood and blood 
products, or semen and sperm of individuals who were already infected. 
Viral Origin 
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Substantial evidence indicates that AIDS originated in Central 
Africa (Clumeck, Sonnett, and Taelman, 1984). Another investigation by 
Saxinger and associates (1985) examined blood samples of a 1972 study of 
Ugandan children and found 65 percent of apparently he althy individuals 
to be positive for HTLV-III/LAV. These blood samples are the oldest 
studied to date and prove the presence of the virus, or a very similar 
organism, several years prior t o i solation in this country. 
Additional support for this hypothesis comes from the identification 
of a virus very similar to HTLV~III in Old World Monkeys, initially in 
the Macque monkey (Miyoski, Taguchi, and Fujuhita, 1982; Guo, Wong-Staal , 
and Gallo, 1984). Essex and coworkers (Essex, Allan, Kanki , McLane, 
Malone, Kitchen, and Lee, 1985) also discussed a simian retrovirus (STLV-
III) which was morphologically and biologically compara ble to HTLV-III. 
Approx ima tely half of the African green monkeys tes ted exhibited 
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antibodies to one or both of these retroviruses (Kanki, Kurth, and 
Becker, 1985). The monkey population in Central Africa has long been 
observed to intermingle with the human inhabitants of the region. The 
potential for exposure to the retrovirus in infected monkeys' body fluids 
could have provided the necessary mechanism for transfer to the human 
population, and combined with the organism's proclivity for mutation, may 
have resulted in the human virus observed today. 
After the recognition of the viral organism as the presumptive 
causative agent of AIDS, the next logical step was to develop an 
accurate, yet inexpensive screening test to identify those individuals 
carrying the virus. An ideal screening test would be sensitive, 
specific, reproducible, inexpensive, rapid, and non-invasive . This 
particular virus has been grown by means of tissue cultures, but this 
method is cost prohibitive, requires specialized equipment, and has a 
long turnaround time. Additionally, only a few locations, primarily in 
the u.s. and France, have the capacity to carry out this procedure. 
The ELISA, or enzyme-linked immunosorbent assay, provided an answer. 
This test pr ocedure had already been refined to detect antibodies to 
HTLV-I, and therefore was easily modified to react with antibodies to 
HTLV-III. This serological test also meets the general criteria for an 
efficient screening test, and subsequently, the ELISA was licensed by the 
FDA for general use in March of 1985. 
The ELISA results are r ead in terms of a ratio dete rmined by the 
optical density of the test sample to a control value. Because this 
method is sensitive, specific, relatively inexpensive, a nd can be read 
rapidly, the ELISA was well suited for use in blood banks, plasma 
centers, and other facilities involved in processing blood or body 
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fluids. The specificity of the ELISA in this case is around 98.6 
percent, while the sensitivity reaches 93.7 percent (Petricciani, 1985; 
Weiss, Goedert, Sarngadharan, and Bodner, 1985). Although no legitimate 
confirmation test exists presently, the Western Blot is another method 
used in tandem with the ELISA. 
The Western Blot is a more costly procedure and has a longer 
turnaround than the ELISA. However, an advantage to this test is that 
specific protein bands, which typically are associated segments of the 
HTLV-III, can be recognized. The primary proteins identified consist of 
a core antigen (p24), an outer membrane protein (gp120), and 
transmembrane envelope proteins (gp41 and gp55) (Sarngadharan, Popovic, 
and Bruch, 1984). A diagram of the general retrovirus structure is 
illustrated in Appendix E. These proteins are recognized t hrough a 
chemical separation by bands according to molecular weights in an 
electrophoretic procedure (Carlson, Bryant, and Hinrichs, 1985). 
The potential for false positive results with the Western Blot is 
uncertain. Although these proteins are integral in the HTLV-III, 
research may also find them to be part of other biological not related to 
the virus in question. In fact, some false positive results have already 
been documented with indi vidual reac tions to the cell line used to grow 
the viral material and not the viral components specifically. Many false 
negatives have a lso been recorded a s patients late in the throes of AIDS 
lose the volume of T-helper cells to such an extent that, in effect , 
antibodies are no longer created. Both the ELISA and the Western Blot 




Understanding of the AIDS virus and realizing the consequences of 
infection have become more clear almost daily. The national and 
worldwide attention of medical and laboratory experts has resulted in 
more information regarding this new epidemic being available in a shorter 
period of time than any other research effort in history. 
Current estimates reveal that one to two million people in the. 
United States could be infected with t he human T-cell lymphotropic virus. 
However, research has demonstrated tha t only 5 to 20 percent of 
seropositive homosexual males actually go on to develop AIDS within one 
to five years (CDC, 1985a). This is based on observations since the 
first appearance of the syndrome in this country. Therefore as time 
passes and more data are gathered, this percentage and associated latency 
period may be adjusted substantially. Some indications are that this 
rate of developing AIDS may already be 30 percent or greater. 
The diagnosis of AIDS is quite obviously only "the tip of the 
iceberg" in the range of problems associated with the HTLV-III/LAV 
infection. The definition of AIDS offered by CDC was admittedly limited 
to provide an epidemiological basis for reporting the severe con s equences 
of the viral invasion. This expanded from the initial definition 
consisting of the occurrence of a reliably diagnosed disease at least 
moderately indicative of cellular immunodeficiency, and the absence of an 
underlying cause for the immune deficiency or any known cause for reduced 
disease resistance. With the licensing of testing for HTLV-III/LAV, the 
CDC definition was broadened in 1985 to include, as another diagnosis 
requirement, a positive test for the HTLV-III/LAV antibodies (CDC, 1984). 
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Recently, CDC proposed and requested comment on a new system for 
classifying and reporting infections associated with the HTLV-III/LAV 
(CDC, 1986).. This system would provide for four classes which describe 
acute responses, asymptomatic infection, persistent generalized 
lymphadenopathy, and other diseases. The last group is divided into a 
number of subgroups describing other infections resulting from the 
presence of the AIDS virus in the human host. This also permits a more 
detailed national reporting of HTLV-III/LAV occurrences, and therefore a 
greater realization of heretofore unidentified sequelae of this 
devastating virus. 
Another change, suggested in early 1986, pertained to consolidating 
the variety of names surrounding the AIDS virus. The subcommittee of the 
International Committee for the Taxonomy of Viruses has recommended 
naming this particular virus the human immunodeficiency virus (HIV) 
(Coffin, Haase, and Levy, 1986). This has met with favorable response 
from the scientific community, and HIV is entering common parlance. 
National trends consistently reflect that the groups with highest 
risk for infection are gay or bisexual males and IV drug users who share 
needles. These two categories, ·as illustrated in Appendix A, represent 
73 and 17 percent of the total cases respectively. I n Oklahoma, these 
two risk groups, respectively, constitute 88 and 5 percent of the total 
cases (Appendix F). The practice of sharing needles for intravenous drug 
use, which has not been shown to be as common a practice in Oklahoma as 
in other areas of the country, may account for the smaller percentages of 
cases occurring in these individuals . 
The high volume of cases in the gay community does not directly 
translate int o AIDS as being a ''gay disease". As mentioned previous ly, 
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the type of contact involved may be significant in exposure to body 
fluids of others, as is obvious in the sharing of needles for drug 
injection. No individual has been demonstrated to be immune to the HTLV-
III/LAV, and the potential for spread through heterosexual contact has 
been proved in several instances. AIDS is not spread by casual contact. 
In the public health approach ~o interrupting the disease 
transmission, education is the .primary weapon. Safer sex practices 
involving the avoidance of exposure to another's body fluids have been 
advertised extensively. The blood banks have requested that high-risk 
individuals refrain from donating blood, blood products, organs, sperm, 
or any other body products. 
This reflects a common sense approach to preserving the integrity of 
the blood supply since the only available screening tests are far from 
perfect. The development of an effective vaccine is still several years 
in the future, and a cure even farther beyond. Until research 
successfully reaches these goals, individuals will have to be r esponsible 




A realistic estimate of hospital admission costs for AIDS patients 
in Oklahoma requires the combined input of several specific factors. 
First, historical costs must be obtained for the known cases managed 
within the State in order to establish a cost basis. A second need is to 
identify an annual inflation index, which would permit equating values 
for expenses incurred in different years. on a common scale. And finally, 
a forecast of annually reported AIDS morbidity must be created. By 
combining these elements, a current dollar amount for expected AIDS 
hospital admissions can be derived for Oklahoma in the short run. 
Information gathering to identify annual reported cases of AIDS and 
to record associated historical hospital expenses occurred prima rily 
through researching existing records. These particular sources included 
both private and governmental materials. Recognizing individual patients 
was necessary to correlate survival times wi th admission charges, 
particularly when more than one facility had been utilized by a specific 
patient on separate occasions. However, due to the extremely sensitive 
nature of public attitudes regarding AIDS and the rights of individuals 
to privacy, the information received from each facility must be protected 
in every sense to safeguard the individual and the participating health 
care facility. Of eight Oklahoma hospitals contacted, only one declined 
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to supply the requested financial data. The institutions that did 
furnish the desired information provided complete financial reports on 30 
AIDS victims. 
The Oklahoma State Department of Health, Sexually Transmitted 
Disease Division retains sole responsibility for maintaining the 
reporting mechanisms for public and private sources and for providing 
statistical data regarding AIDS diagnoses within the state. This source 
provides the only complete records of individual cases reported i n 
Oklahoma. The Division also has the ultimate responsibility for 
protecting the confidentiality of both individuals and facilities, and 
therefore access to this information is, of necessity, closely guarded 
and available only to a very few. Statistical reports, relevant to each 
case diagnosed, are forwarded by code number and not by name to the 
Center for Disease Control in Atlanta for monitoring disease trends on a 
national level. Overall general statistics are made available to the 
public, however individual identities, specific geographic locations, and 
the reporting facilities and attending physicians remain confidential to 
protect all those involved and to avoid extreme and unwarranted public 
reactions. This agency was the source for annual case totals, individual 
survival times, and the specific hospitals reporting new diagnoses of 
AIDS. This allowed the targeting of facilities that possessed financial 
data pertaining to specific patients over the reporting years. 
Summarizing the amount of charges incurred in hospital admission per 
AIDS patient was the result of direct contact with the managing 
facilities. In Oklahoma, eight hospitals processed the admissions of 87 
pe rcent of the total cas es reported. Seven of these f acilities responded 
to the r equest for admission figures with complete accounts, although 
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some of the earliest financial records were no longer available. The 
accumulated reports did provide statistics on 71 percent of the Oklahoma 
AIDS patients through calendar year 1985. This is a compilation of the 
most complete information accessible. 
Finding a price index for hospital charges in Oklahoma proved very 
difficult. Direct contact with the Oklahoma Health Planning Commission, 
the Oklahoma Hospital Association, and even the Federal Health Care 
Administration could provide no indices for Oklahoma. The latter federal 
agency did verbally provide a consumer price index for hospital costs on 
a national average. This set of indices was therefore employed as a 
guide in adjusting annual rates for 1983-85 to an overall 1985 dollar 
level. 
Forecasting Technique 
Creating a forecast for anticipated morbidity is a more restricted 
proposition due to the limited amount of data available in terms of the 
short period of history since the recognized emergence of AIDS. As 
previously mentioned , with only three years of recorded data relating to 
AIDS diagnoses in Oklahoma, many forecasting techniques are severely 
limited in application. I n general, many of the accepted time series 
forecasting me thods require much more than three data points for very 
meaningful interpreta t ions (Makridakis, Anderson, Carbone, Fildes, Hibon, 
Lewandowski , Newton, Parzen, and Winlder, 1984). However, one relatively 
simple, but realistic, method of predicting new cases on an annual basis 
is to g raph the known morbidity and extend t he resulting line into the 
short-run future. Finding t he shape of a line which best fit the 
recorded data points would permit an acceptable forecast based on the 
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extension of this line for three future periods. To carry this line very 
far would be quite risky considering the small base of historical data 
that exists. 
The Interactive Financial Planning System (IFPS) provides a program 
which will effectively meet these needs. This system, developed by 
Dr. Gerald R. Wagner, is a user friendly mainframe computer program with 
a large variety of related functions (Gray, 1983). Primarily des igned 
for business application, the system offers many mathematical and 
statistical operations in addition to the basic financial functions. The 
system is becoming more popular for strategic planning in companies with 
mainframes because of its easy commands and functiona l variety. 
IFPS has three specific options available to address the current 
problem unde r the POLYFIT command. POLYFIT specifically enable s the user 
to extrapolate a single variable into the future. POLYFIT(O) averages 
all past values and assumes future values equal to this average. 
POLYFI T(1) f its a l i near regression line to the given data and extends 
this to determine future values. The third option, POLYFIT( 2), 
establishes a best-fit quadratic equation to the data points and 
ex trapola tes future values to the chosen limi ts. All three options may 
be empl oyed i n a s ingle run with the given set of da t a . 
Resul ts and Foreca sts 
The cumul at ive t ot a l of AIDS ca ses in Oklahoma has reached 42 in the 
first three years of reporting . This breaks down to five reports in 
1983, 12 in 1984, and 25 in 1985. These cases de termined the 
i dentifi cati on of eight hos pi t a l s in Oklahoma which should have the 
desired financial data on hospi t al admission charges. Records on 30 
patients were accumulated for this study. 
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In conjunction, the national hospital cost indices were obtained and 
were noted to reflect a decline in the rate of increase over the period 
of study. In comparison with 1983's rate of 12.0 percent over 1982, the 
indices needed for cost adjustment illustrated dramatic declines. For 
1984, the rate was 9.2 percent over 1983 charges, and the 1985 index was 
only 7.0 percent greater than 1984. No estimates were available for 1986 
or beyond. By applying the appropriate indices to expenses incurred in 
the corresponding years, charges accumulated in each calendar year could 
be equated to a standard scale, which in this example is 1985 dollars. 
This affords a realistic picture of AIDS admission expenditures 
anticipated over the next three years. 
Incorporating these indices with the financial data obtained on the 
30 Oklahoma AIDS cases revealed a sum total of $747,316. This averages 
just under $25,000 per diagnosed patient. The individual charges ranged 
from a low of $3,957 to a high of $77,659, ultimately depending upon the 
patient's survival and type of opportunistic infection encountered. The 
significance of this is magnified in the context of the mean survival 
time of only four months. 
In terms of admission days, the averages were computed for 25 
individuals in two categories, those already deceased and those still 
surviving a t the end of 1985. For those deceased AIDS victims, the 
average number of days of hospital admission equalled 35. In contrast, 
those who were still living averaged 37 hospital admission days through 
the end of 1985. Again, these are actua l admission days and do not 
r epresen t any outpa tient visits or office exams. Variations were 
apparent in these figures also as hospital admissions ranged from 3 to 
104 days. 
A further computation of cost-per-day charges revealed $708 for 
those AIDS victims who had died as opposed to $582 for individuals who 
still were alive. This significant difference may be a result of the 
living patients not yet approaching the severe physical collapse 
occurring near time of death and the extreme cost and intensity of the 
associated medical management at that point. 
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In the IFPS program, all three specific POLYFIT options were 
employed to evaluate which method provided the most realistic 
expectations based on the observed data. POLYFIT(2), wi th the use of a 
quadratic equation, developed the most reasonable forecast of AIDS 
morbidity for Oklahoma. In this instance, the reported cases of AIDS for 
1983-85 were entered into the program, and an extrapolation for 1986, 
1987, and 1988 were requested. The resultant predictions for the next 
three years are anticipated to be 44, 69, and 100 cases respectively . 
Appendix G graphically illustrates the known and expected AIDS morbidity. 
Although variations in reports make direct evaluation difficult, 
these forecasts are supported in ·comparison with both national and 
regional trends. In the United States, the reported AIDS cases have 
increased each year from the 12 attributed to 1979 to the 6,571 in 1985 
(see Appendix D). However, the r a te of increase over this time period 
ha s slowed by an average of 28 percent . In comparison, the rate of 
increase for Oklahoma's known and predicted volume of AIDS diagnoses 
decreases by an average 25 percent. 
I n t erms of a regional comparison, the s tate of Texas provides very 
useful information. Texas firs t reported a case of AI DS in 1980, and 
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through 1985, the cumulative totals reflect 80 percent in the homosexual 
or bisexual risk group and three percent in the intravenous drug user 
segment. Thus, Texas offers a patient population similar to Oklahoma in 
risk factors, and yet, has a history of AIDS reports three years longer 
than Oklahoma. For the calendar years 1980 through 1985, Texas reported 
2, 8, 29, 128, 320, and 598 AIDS cases respectively. The average rate of 
increase in these reported cases decreased by 20 percent. This rate also 
compares in reasonable fashion to the average decline in the rate of 
increase predicted for Oklahoma. 
Obviously, the predictions represent very significant increases. 
The 1986 value of 44 is more than the cumulative total for the three 
years of known AIDS case reports in Ok l a homa . These new cases would 
bring Oklahoma's cumulative AIDS morbidity total to 86. If the average 
hospital admission charges per AIDS patient, in 1985 dollars, are applied 
to this anticipated morbidity, the debt will reach $1,100,000. Very 
conservatively, this would represent 1,450 admission days attributable 
just to the newly diagnosed. 
An additional reported 69 cases of AIDS in 1987 could result in an 
additional financial burden of $1,725,000. This is $625,000 higher than 
1986. Inflation rates for this year could bring this amount even higher. 
The required hospital admission days would rise to 2,415. 
Finally, in 1988, the first-time diagnoses of AIDS may reach 100 
individuals. This would translate into $2 ,500,000 in admission expenses. 
In the context of 1985 dollars, this is more than double that anticipated 
for 1986. I n hospital admits, this reflects 3,500 days. 
The three-year expenditure for hospital expenses totals $5,325,000, 
with 7,365 da ys of admission. This a ssume s a constant avera ge fo r 
admissions equalling that already observed. This is well on the 
conservative side as increases in survival times will have a definite 




Difficulty of the Situation 
The results obtained in this evaluation are based upon observations 
of the existing, yet admittedl y limited, data on AIDS patients in 
Oklahoma. The documented survival times for these patients, at an 
average of four months, is drama tically lower than the 18-month average 
reported on a na tional scale. If the Oklahoma survival period begins to 
approach that seen nationally, the overall expenditures for maintaining 
AIDS victims will increase accordingly. However, the degree of the 
effect, brought on by a longer survival rate, will have to be determined 
as the bulk of these particular expenditures accumulate at time of 
diagnosis and at time of death, with sporadi c admissions in between these 
points of r e ference. A four-month survival period severely limits the 
opportunity to draw any meaningful concl usions in comparing tota l cost 
increase with survival times. 
The overa ll figures indeed represent a conservative stance in 
pla nning for f uture costs. This study only takes i nto account 
expenditures directly related to hospital admissions of AIDS patients. 
Not included are expenses for ou tside treatment, outpatient therapy, or 
even physician c onsulta tions. Also, the morbidity figures f or Oklahoma 
i nc l ude only patien ts livi ng i n the Sta te at t he t i me of diagnos is . 
Whil e j ust one or two i ndividuals moved away a fter diagn osis, a t least 20 
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patients, diagnosed elsewhere, have returned to Oklahoma to live out what 
time they have left. These pat i ents will require the services of the 
hospital facilities, as will those individuals suffering from HIV-related 
maladies which do not meet current CDC criteria for AIDS diagnosis. The 
number of people included in this last category is unknown since no 
reporting mechanism exists for recording that specific condition. 
However, that number is believed to be much larger than the number of 
diagnosed AIDS cases. 
The anticipated admission costs are very significant. Individual 
charges ranged from approximately $4,000 to over $77,000. The rise from 
an estimated $1.1 million in 1986 to $2.5 million in 1988 represents a 
two-fold increase as reflected in 1985 dollars. Inflation factors could 
make this gap even greater. Additionally, a minimum total of 3,500 
admission days in 1988 for newly diagnosed AIDS cases would constitute a 
significant need for hospital space. This is even more poignant in view 
of the historical situation in which eight hospitals have managed nearly 
90 percent of the reported AIDS cases. Other hospitals will no doubt 
become more involved as case numbers grow, yet the tendency for the bulk 
of the AIDS reports to occur in the urban areas of Oklahoma City and 
Tul sa is not expec ted to undergo any significant shift . 
The hospital facility usage will not require any unmanageable 
adjustments in Oklahoma. The major metropolitan areas have enough total 
capacity to handle the predicted volume of AIDS cases. However a matter 
of deep concern revolves around the payment of the rapidly mounting costs 
incurred by the individua l patients. This is the crux of the extreme 
financial burden, "Who will pick up the payments?" This wi l l become more 
of a priori t y as the AIDS morbidity rises. 
The individual diagnosed with AIDS is most often incapacitated to 
the point that he/she is unable to maintain employment. Therefore, 
unless independently wealthy, most AIDS victims have a very difficult 
task in meeting day-to-day expenses, even without having to face the 
burden of high medical charges. And this burden is significant with a 
$25,000 bill accumulated in roughly four months. Longer survival times 
will certainly acerbate this problem if other circumstances remain 
constant. In almost every case, the patient is unable to pay the 
hospital bills without some form of outside assistance. 
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For those employed at the time of AIDS diagnosis, insurance programs 
and company health plans have covered a great share, but not necessarily 
all, of the incurred hospital expenses. Consequently, these companies 
cannot afford, over time, to continue to finance the level of expenditure 
related to potential increases in AIDS admissions. This difficulty is 
compounded by the primary occurrence of AIDS in those age groups that 
routinely require less costly medical procedures and historically have 
financially supported other aspects of the overall health care program. 
As a result, the insurance industry has begun studying and moving toward 
avoidance of AIDS-related expenses (Shahoda , Lashley, and Firshein, 
1986). This has been a pproached through requirements for HTLV-III 
antibody testing as part of an acceptance physical examination process 
and by excluding AIDS-related conditions from coverage. Instances of 
insurance being denied to those with positive antibody tests have already 
become common. Another suggested alternative is to develop specific AIDS 
insurance policies along the lines of cancer insurance programs. Those 
participating i n this type of schedule would, of course, pay a much 
higher premium. 
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Other potential, and often expected, sources of financial aid are 
governmental programs. In many parts of the United States, local 
governments have establ~shed various forms of financial assistance for 
AIDS victims. For the most part, these efforts have not been of 
sufficient magnitude to support anything beyond an individual's daily 
survival, if that. Paying hospital admission charges would not even be 
considered, and with the prevailing economic conditions in Oklahoma, this 
has very slim potential for change. 
The next level of possible government aid is the State of Oklahoma. 
Here again the economy will severely limit any subsequent response. 
Financial support will most likely be directed to day-to-day survival for 
the patient with AIDS. However, lobbying activity to the State 
Legislature by the hospital associations may bring indirect relief to the 
private institutions, especially through greater funding for teaching 
hospitals. By giving AIDS victims greater access to the "free" 
facilities, pressure to admit these patients to local private hospitals 
will decrease. However, with only one teaching hospital in the State, 
and that being located in Oklahoma City, access for patients is still 
constrained. 
On the federal level, AIDS patient support is again limited. Most 
federal grants have been directed at screening tests or research. 
However, Supplemental Security Income (SSI) payments, while automatically 
a llowed to those with AIDS diagnoses for disability, provides monthly 
payments of less than $300 to individuals, and this only if they have no 
other income and meet strict regulations on property ownership. The 
current limit on personal resources is $1,600. This provides bas ic 
survival monies. Another potentially applicable federal/state program is 
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Medicaid, which does pay hospital costs for disabled patients. A problem 
arises in that the required period of infirmity for disability 
qualification is 24 months. With AIDS patients in Oklahoma surviving 
only four months, few can qualify for this program. 
The last alternative, that many hospitals have been forced to 
accept, is that of just absorbing the loss . Some of this amount can be 
written off for tax purposes as bad debt o~ as good will. However, in 
the majority of cases, the unpaid bills are extremely high. As a direct 
result of unacceptable losses, some of the institutions have refused to 
admit AIDS patients or have attempted to refer them to another facility. 
This action not only creates hardship for the individual, but promotes 
ill will among the hospitals and can damage the health care reputation 
within the community. This can also open the door for lengthy and costly 
law suits. 
Nevertheless, several positive courses of action are available in 
managing this very difficult circumstance which will obviously become 
more severe in the near future. While little can be done to cure or 
immunize against AIDS, much can be done to avoid s preading the infection 
and to manage those case s which already exist. 
Positive Approa ches 
Education targeted to high risk groups and the community in general 
is the most effective wea pon against the s pread of AIDS currently. 
Governmental agencies on all levels are becoming more involved in this 
type of activity, as are private organizations, such as the American Red 
Cross. The hospitals, individually and collectively, stand to gain in 
the long run by a decrease i n the number of new AIDS cases. Even if 
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financial support for patients is increased through various agencies, the 
dramatically rapid rise in AIDS morbidity will more than overshadow the 
available r elief. Therefore, hospitals stand to benefit, in the long 
run, from encouraging or even becoming involved in directed educa tional 
efforts. 
Another factor, contributing to the high hospitalization costs 
associated with AIDS, has been unnecessary admissions. Because the 
syndrome has presented such a new medical curiosity, admission had become 
a standard procedure for every reported ailment. This activity has no 
foundation in the medical management for the individual patient and has 
certainly resulted in a significant number of excessive hospital days. 
Many of the AIDS-related maladies can be effectively controlled on an 
outpatient basis, which is a much cheaper and more cost effective 
attitude without compromising patient care. 
In accordance with sound management, the prevention of antibody-
stimulating infections can help retard the viral spread within the host 
organism. The use of killed-virus vaccines has proven to be effective. 
Through employment of these types of vaccines to immunize against such 
diseases as influenza, pne umococcus, a nd hepa titis, the immune system has 
less opportunity to become stimulated, and thus reduces the chance of 
spreading the invading HIV. Thus, with preventative medical action, the 
hospital should see a reduce d need for admissions by potentially 
decreasing the number of r ecurrent infections. 
Another less expensive alternative is care for the AIDS patient 
outside the hospital setting . In the past, AIDS victims who only 
required intermediate medical care wer e forced into the skilled care 
hospital facilities simply because the intermediate level nursing was not 
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available to them. For those patients able to stay at home, visiting 
health care nurses are a viable means of medical assi stance. Essentially 
not a free service, the cost is far less than hospital admission. This 
is a program that is currently seeking federal aid and could be 
implemented as an outreach hospital program. In fact, many hospitals 
already have initiated similar activities for aiding the elderly and 
other classes of homebound patients. 
For those patients unable to maintain a home, or with no family, 
another type of program is deve l oping. A few communities in Oklahoma 
have undertaken the task of providing a r esidence for AIDS patients 
requiring care on the intermediate or lesser levels. Staff ing functions, 
in general fashion, seek results similar to that realized by home health 
nursing. However, support from local hospitals would still be invaluable 
in maintaining such facilities. This also would tend to be more 
economical in the long r un as costs related to admitting these patients 
to hospitals would f ar exc eed the required inves tment. 
Finally, more grants are becoming available to employ experimental 
drugs in managing AIDS cases. The Federal Drug Administration is 
permitting wi der use of these types of med i cations in light of the 
extreme mortality associated with AIDS. The s e grants have the effect of 
paying much of hospital admission costs. Therefore the participating 
f a cility would have the opportunity to realize reimbursement for charges 
tha t would otherwise be lost. 
In summary, Oklahoma hospitals are going to have to face a 
sign i ficant and growing financial dra in inherent in the s heer number of 
de velopi ng AIDS ca ses. No one singl e answer will cure a ll the ills, but 
many alterna tive s, some mos t e ffective in combina tion, are available . 
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With no medical cure or realistic preventative on the horizon, hospitals 
need to employ more efficient and imagina tive methods of financial 
planning concerning AIDS patients without sacrificing sound medical care. 
AIDS morbidity will be increasing dramatically in a very short period of 
time in Oklahoma. Plans of action by hospitals and their associations 
should be placed in motion now rather than being forced to react later as 
the situation intensifies. 
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DEMOGRAPHIC BREAKDOWN OF REPORTED 
AIDS CASES IN U.S . 
41 
A£IPIRED D-ti.NifflCIDCi SYKm£ (AII:6) 
\HlQ.Y 9.RVEill..A!'U RElUCI'* - l.NinD STAlES 
Aiffi ICfJ.VIX{ 
!llfiiD STAm> CASES REKKll'!D ro en: 
QNIER FCR NtcrlaJS ~ 
wmlt5 fCR D~ cnrnn. 
I):>ceabp..r .l), 1965 




a.sFS (%) IV.N; (%) ,, IJlSF..\SE"' GOPt** 
Both I<S 800 F(l> 
15 w1 tlnJt PCl' 
pa» vitlrut I<S 
CASES {%) 























I PATITh'T <m.lPS** 
~ cc Bisexual Men*** 
Int:raveroJS (IV) Dn.€· U;er 
l:eiophl lia/Coagulatioo Disorder 
Heterosexual ODtact tt t 
Transfusicns w1 th 
Blocrl/Hlocrl Prcrlucts 
~ of ~ NxNe/Otle! ***lc 
Total 
l:lenophilia/Coagulatioo Dioorder 
Parent with AIDS/ or at 
1ncreaserl risk for AII6tt t t 
Transfusioo vi th Blocxl/ 
Bl£xxl Pro:hiCts 
~ of ~ ~/Otler 
Total 
3. 







4 (2) 4 (100) 
6 (3) 6 (100) 
129 (56) ~ (70) 
~ (39) 36 (40) 
129 (100) 136 (59) 
All.JLT/~ 
~ (%) 
\o.\li te , IX>t Hispenic 9429 (W) 
~ IX>t Hisp8nic 3868 (25) 
H:ispmic '1125 (14) 
Other 86 (1) 
l.hkna.n 111 (l) 
Total 15719 (100) 
AUJLT I AJXJ....ES:£Nr 
WJE.S (%) F£W\lE) (%) 
11513 (78) - (-) 
2139 (15) 545 (53) 
119 (1) 4 (0) 
2B (O) 151 (15) 
154 (1) 98 (10) 
740 (5) 228 (22) 
14693 (100) 1026 (100) 
F£DIA1Rlct t 
~ (%) FEWJ.ES (I) 












~ (%) IFAnts (%lEAD) 
899 ( 6) --s=i9 ( 64) 
2965 (19) 1146 (39) 
9142 (57) 482~ (53) 
2942 (18) 1612 (55) 
15948 (100) 8161 (51) 
PEDIATRict t 'lUTAL 
o.sES (%) CASES (%) 
44 (19) . 9473 (59) 
136 (59) 4004 (25) 
46 {20) 2271 (14) 
0 (0) 86 (1) 
3 (1) 114 (l) 












. 172 (75) 
34 (lS) 
. l2 (5) 
7:19 (100) 
*1he:se data are· prcNisiooal . . 
tl<S • l<ap:lsi ' s sarcam; · F(l> ·• . Pre.mx:ystis ca::rinii ~; 01 • Otrer ~tic .infect:icns 
*'IQ-oops listed are ordered hierarchically; cases vi th a.tl. tlple charact.erl.sti.c:s are tarulated ooly 
in .tf-e grrup listed first. . . 
ttlnclWe6 patiffits lrner .13 ,ears··'of age at i::1.ae of, diBgra;is. 
***1.267·'(11%) ·Of .. ~·men · aloo reponecf·~. used IV~ 
tt M th a persro· With Am> or 4t. risk. fer AirS 
****Incluie:s l11 ·persOns born in cnnt:rtes in ~ch. DDSt AIIl5 cases have. not beena&sOciated with ~· risk . 
.fact.on;. 
ttttEptcianinl cv;fc data ~est t:ransmiBsioo fran infected 110t1-er to c:hild before. at . or sl-mtly lifter tte 
t:.i.ue of b1rt:h. 
APPENDIX B 
SAMPLE OF AIDS CASE REPORT FORM LISTING 
DIAGNOSTIC OPPORTUNISTIC INFECTIONS 
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IDS BRA NCH 
1;PARTM ENT OF HEALTH AND HUMAN SERVICES 
IIBLIC HEALTH SE RVICE 
NTERS FOR DISEASE CONTROL 
!LANTA, GEORGIA 30333 
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 
CONFIDENTIAL CASE REPORT 
FOR M APPROVED 
OMB NO. 0920·0009 
44 
This report is authorized by law (Sections 304 and 306 of the Public Health Service Act. 42 USC 242b and 242k). Response in this case is voluntary for federal 
rernment purposes, but may be mandatory under state and local statutes. Your cooperation is necessary for the understanding and control of AIDS. Information in 
! surveillance system that would permit identification of any individual or establishment is collected with a guarantee that it will be held in confidence. will be used 
pr for the purposes stated in the assurance on the reverse of the form. and will not otherwise be disclosed or released without the consent of the individual or the 
11blishment in accordance with Section 308(d) of the Public Health Service Ac t (42 USC 242m). 
~TE FORM COMPLETED 
SOUNDEX HEALTH DEPARTMENT USE ONLY CDC USE 
NAME CODE STATUS OF TH!S REPORT REPORTING HEALTH DEPARTMENT rn 110 . Day Year [J] New Case State 
IJITJITJ I I I I I IJ] Update Report City /County I I I I I 
BASIC PATIENT INFORMATION 
~le of Birth Age at Diagnosis Current Status Date of Death CDC PATIENT NUMBER 
b cTIOJ 
of AIDS [DAtive [f]oead : Mo. 0JY YeJ r I I I I I I I 
Years rn OJOJrn [i] Unknown STATE PATIENT NUMBER 
p Race/Ethnicity I I I I I I I I I I 
Male [i} White (not Hispanic) [I) Hispanic ~American Ind ian/Alaskan Native CITY/COUNTY PATI ENT NUMBER 
Female IJ] Black (not Hispanic) 0Asian/Pacific Islander [g) Not Specified I l l I I I I I I I 
;SI DENCE AT ONSET OF ILLNESS SUGGESTIVE OF AIDS: C OC USE 
CITY COUNTY STATE I I I I I I I I I I f' Zip Code I I I I II I I 1rn 
State/Country nty 
HOSPITAL 
SPITAL WHERE DIAGNOSIS OF AIDS ESTABLISHED: II 
. e CITY STATE 
'r, State I I I I I rn 
II. DISEASES AT LEAST MODERATELY INDICATIVE OF CE LLULAR IMMUNODEFICIENCY AND AIDS 
EASE ( Oleck all that apply ) 
1 Kaposi' s sarcoma 
~Pneumocystis carinii p neumo nia 
1 Toxoplasmosis (exclude if only in liver r;tBra in/ loJ~her 
spleen, m uscle, or lym ph nodes) ~CNS ~S1te 
9 c ryp tosporidiosis with diarrhea persisting > 1 mo. 
Cytomegalovirus infection histopathologically docume nted (exclude 
I if only in liver, nodes. or mononucleosis syndrome, or diagnosis by 
serol ogy or cu lture alone) 
1 Primary lymphoma of brain 
~ P rogressive multifocal le ukoencephalopathy 
(Papovavirus infect ion, bra in) 
ll Candida esophagit is 
il Atypical (non-tuberculous) mycobacterial infectio n, d isseminated, 
e.g. bone marrow or multiple organ involvement (exclude if only 
pulmonary and/or lymph node infection) 
Species: OJ M. avium·intracellulare m Other, (Specify): 
I Crypt ococca l infection (exclude pulmo nary only) 
[iJ Meningit is [l]Other inte rnal organ [i]Biood 
I Chronic mucocuta neous herpes simpl"x infec tion persisting > 1 mo. 
Date of Specimen Method of Oi.3.gnosts (Check One) 
or Diagnosis 




OJOJ [II @] 
OJOJ OJ @] 
OJOJ [II @] 
OJOJ GJ @] 
OJrn OJ @] 
rnOJ OJ @] End oscopy /Au topsy wit h 
culture, m icroscopic, or 






Microscopy, Culture , 
or Antlqen Other 
OJrn w [QJ 
OJrn m @] 












Gc 50 . 42 I·B5 1st Copy - CDC 
APPENDIX C 
AIDS CASES IN U.S . BY SELECTED SMSA'S 
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All AIDS Cases Per Million Population (from the 1980 Census), by Standard Metropol itan Statistical Area 
(SMSA) of Residence, Reported from June 1, 1981 to December 30, 1985 - United St ates 
SMSA of 
Residence 
New York, NY 
San Francisco, CA 
Miami, FL 
Newark, NJ 
Los Angeles, CA 
Elsewhere 
(irr espective of SMSA) 









Table total includes 8 cases diagnose d prior t o 1979. 
Center for Disease Control 
U.S. Printing Office 
Cases 
Percentage Per Mill ion 
Of Tot a l Popul ation 
32 555. 1 
ll 536 .5 
3 306. 3 
2 202.4 
8 177 . 6 
43 33. 9 - - -




REPORTED AIDS CASES AND FATALITY RATES BY 
HALF-YEAR OF DIAGNOSIS IN THE U.S. 
47 
All Reported Cases of AIDS And Ca se-Fatality Rates by Half-Year of Diagnosis, 1979 - December 30, 1985 , 
United States 
Number of Number of Case-Fa talit y 
·Cases Known Deaths Rate --
1979 Jan.-June 3 2 67% 
July-Dec. 9 8 89 % 
1980 Jan.-June 18 15 83% 
July-Dec. 29 27 93% 
1981 Jan.-June 86 72 84 % 
July-Dec. 174 14 7 84 % 
1982 Jan.-June 360 277 77% 
July-Dec. 632 462 73% 
1983 Jan.-June 1182 84 9 72 % 
July-Dec. 1535 11 25 73% 
1984 Jan . - J une 2340 1548 66% 
J uly-Dec. 3001 1622 54 % 
1985 Jan.-June 3792 1401 37% 
July-Dec. 30 2779 602 22% 
Totals 15948 8 161 51% 
Table total includes 8 ca se s diagnosed prior to 1979 . Of the se 8 cases, 4 a r e kno\m t o have di e d. 
Center f or Disease Control 




DIAGRAM OF RETROVIRUS 
49 
Membrane-~ 
Core protein , 1 1 • ct 
RETROVIRUS 
Knob or spike (glycoprotein) 
~ "~ _ Reverse transcriptase 
~ ...... ~ \~ Nucleoprotein 




CUMULATIVE TOTALS OF AIDS CASES 
IN OKLAHOMA THROUGH 1985 
51 
52 




OKLAHOMA CASES REPORTED 
Known 
Cases Deaths % Dea d 
KS without PCP 5 1 20% 
Both KS and PCP 2 1 50% 
PCP without KS 26 17 65% 
Other Infections 9 3 33% 
42 22 52% 
(Mean survival f rom date of diagnosis - 4.0 months) 
AGE RACE 
< 13 White 35 83% 
13-19 Black 6 14% 
20-29 l3 Indian 1 2% 
30-39 22 Other -- % 
40-49 3 Total 42 




Male 42 100% 
(Mean age 34 years) Female 
Total 42 100% 
TRANSMISSION CATEGORIES 
Homosexual or Bisexual Men 37 88% 
I. v. Drug User 2 5% 
Blood Transfusion 1 2% 
None/Other 2 5% 
42 100% 
APPENDIX G 
GRAPHIC REPRESENTATI ON OF KNOWN AND PREDICTED 
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